Betul Apaydın Yıldırım, Tuba Dogan, İsmail Bolat, Ali Can Ozcan, Rabia Kocak
{"title":"NADPH 氧化酶抑制剂阿朴昔宁通过 Bcl-2、Bax、caspase-3 和 NF-κB 信号通路对人肺癌 A549 细胞的影响。","authors":"Betul Apaydın Yıldırım, Tuba Dogan, İsmail Bolat, Ali Can Ozcan, Rabia Kocak","doi":"10.1007/s00210-025-03833-5","DOIUrl":null,"url":null,"abstract":"<p><p>Apocynin (AP) is an anti-inflammatory drug with different therapeutic effects. This study aimed to investigate the antiproliferative, apoptotic, and antioxidant effects of AP on human lung adenocarcinoma cells (A549) and to investigate the effects on Bax, Bcl-2, NF-κB, and caspase-3 signaling pathways that may play a role in the pathogenesis of lung cancer. Cell viability was measured by MTT and cell apoptosis, and detection of cell death was measured by ELISA. IMA, AOPP, MDA, and GSH levels, SOD and CAT activities, and Bcl-2, Bax, NF-κB, and caspase-3 expression levels were analyzed from the obtained cell lysates. As a result, according to the findings obtained, IMA and MDA levels decreased in the A549 cancer cell line, while GSH levels and SOD and CAT activity increased. It was determined that the application of apocynin to A549 cells significantly reduced cell viability and directed the cells to apoptosis, increased Bax, NF-κB, and caspase-3 expression, and decreased Bcl-2 expressions. Since all of the data obtained were not found in the literature about the use of apocynin in the A549, the study conducted is pioneering. Our study demonstrates the potential of apocynin for cancer therapy possibly targeting the apoptotic pathway.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of NADPH oxidase inhibitor apocynin on human lung cancer A549 cells via Bcl-2, Bax, caspase-3, and NF-κB signaling pathway.\",\"authors\":\"Betul Apaydın Yıldırım, Tuba Dogan, İsmail Bolat, Ali Can Ozcan, Rabia Kocak\",\"doi\":\"10.1007/s00210-025-03833-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Apocynin (AP) is an anti-inflammatory drug with different therapeutic effects. This study aimed to investigate the antiproliferative, apoptotic, and antioxidant effects of AP on human lung adenocarcinoma cells (A549) and to investigate the effects on Bax, Bcl-2, NF-κB, and caspase-3 signaling pathways that may play a role in the pathogenesis of lung cancer. Cell viability was measured by MTT and cell apoptosis, and detection of cell death was measured by ELISA. IMA, AOPP, MDA, and GSH levels, SOD and CAT activities, and Bcl-2, Bax, NF-κB, and caspase-3 expression levels were analyzed from the obtained cell lysates. As a result, according to the findings obtained, IMA and MDA levels decreased in the A549 cancer cell line, while GSH levels and SOD and CAT activity increased. It was determined that the application of apocynin to A549 cells significantly reduced cell viability and directed the cells to apoptosis, increased Bax, NF-κB, and caspase-3 expression, and decreased Bcl-2 expressions. Since all of the data obtained were not found in the literature about the use of apocynin in the A549, the study conducted is pioneering. Our study demonstrates the potential of apocynin for cancer therapy possibly targeting the apoptotic pathway.</p>\",\"PeriodicalId\":18876,\"journal\":{\"name\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00210-025-03833-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-03833-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Effect of NADPH oxidase inhibitor apocynin on human lung cancer A549 cells via Bcl-2, Bax, caspase-3, and NF-κB signaling pathway.
Apocynin (AP) is an anti-inflammatory drug with different therapeutic effects. This study aimed to investigate the antiproliferative, apoptotic, and antioxidant effects of AP on human lung adenocarcinoma cells (A549) and to investigate the effects on Bax, Bcl-2, NF-κB, and caspase-3 signaling pathways that may play a role in the pathogenesis of lung cancer. Cell viability was measured by MTT and cell apoptosis, and detection of cell death was measured by ELISA. IMA, AOPP, MDA, and GSH levels, SOD and CAT activities, and Bcl-2, Bax, NF-κB, and caspase-3 expression levels were analyzed from the obtained cell lysates. As a result, according to the findings obtained, IMA and MDA levels decreased in the A549 cancer cell line, while GSH levels and SOD and CAT activity increased. It was determined that the application of apocynin to A549 cells significantly reduced cell viability and directed the cells to apoptosis, increased Bax, NF-κB, and caspase-3 expression, and decreased Bcl-2 expressions. Since all of the data obtained were not found in the literature about the use of apocynin in the A549, the study conducted is pioneering. Our study demonstrates the potential of apocynin for cancer therapy possibly targeting the apoptotic pathway.
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.